The flexibility of the plant-based system, combined with its low cost and ability to massively scale, may provide vaccine protection not only to citizens of the United States, but also to many parts of the world that cannot currently afford vaccines, said Dr. Barry Holtz, President of G-Con.

We expect vaccines against influenza, including seasonal influenza, to be among the earliest applications of the iBioLaunch technology, said Robert Kay, Chairman and Chief Executive Officer of iBio. In the new GreenVax facility, G-Con ™s modular production technology should significantly enhance the economy, speed and flexibility advantages of our system for application to a broad range of biologic products.

Research and development for the GreenVax Project will occur on a secure, 21-acre site on the campus of the Texas A&M Health Science Center in Bryan, Texas. There will be a custom-designed, 145,000-square-foot bio-production facility that is being constructed by G-Con. The facility has been optimized to achieve the goals of this project, yet remains expandable as required without interruption of core operations. The projected final scale capacity of the facility is 100 million doses per month. Although there are currently no approved plant-based flu vaccines, a clinical development program for influenza vaccines produced with the iBioLaunch platform is underway.

SOURCE iBio, Inc.